Australia's largest stock trading and investment forum Australia's #1 stock forum

ALT

0.00%

0.5¢ analytica limited

Kind of agree. Good value here.

First 49 Last

Share
Profile

Follow
wubing

4,109 Posts.

62

08/01/17

17:19

Post #: 21751031
Share

Originally posted by PeasantOne ↑

Having decided ALT will probably take off, for the sake of having a concept of direction I've tried to determine a realistic market by getting figures for moderate to severe sufferers i.e. those who'll be willing to pay. No shortage of studies out there but results are all over the place due to different methodologies and definition of incontinence. However I've noted some of the more concise studies which could be cross referenced and matched up.
- 150m globally. (this is 5-6% of females over 15. 6% was a fairly consistent number)
- 3-17%. (5% is 150m; 3% is 90m; 10% is 300m; 17% is not realistic imo)
- Up to 10%. (maybe in the long term with excellent marketing, but 1 in 20 or 1 in 100 seems ok)
1% was also a consistent number and this sits comfortably with me.
30-40m sufferers in US & EU. (1% is 3.5m)

UI related operations - 10k in UK; 400k in US. Per capita those figures are contradictory; initially I was going to scrub the US figure, but 400k is one quarter of 1% so I believe it's the UK number which should be ignored. So - 400k being worst of the worst times 2 for Western Europe etc ( our more immediate markets) = 800k sales.
A good study indicated 50% of sales will be from worst cases and 50% from the rest. Applying that to the operations gives 1.6m sales. In a recent post I determined about 1.3m. One million sales will give us great success.
On a global basis this would translate to 8-9m needing operations, which is 5-6% of 150m; 15-20m including moderate sufferers.

In all 1.5m sales seems minimum. 9m seems the number possible long term, say post 2022. 4.5m gives us about $60m p.a.
The great beauty is the annual subscription model. In 1st world countries moderate to severe sufferers will pay up to $1400 p.a. depending on degree of resolution. Pericoach is priced to sell.
A couple of factors to support all this - women are increasingly open to discussing incontinence so word of mouth sales will be a factor; women do not want an operation.

So the above is a bit vague and rough, but it is a guide and is conservative. If pericoach works even reasonably we'll do very well indeed.

Expand

Kind of agree.
Good value here.

ALT Price at posting: 0.6¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Dreadnought achieves 84% indicated resource at Star of Mangaroon

There are more pages in this discussion • 68 more messages in this thread...

First 49 Last

Add ALT (ASX) to my watchlist

Kind of agree. Good value here.

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Dreadnought achieves 84% indicated resource at Star of Mangaroon